Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 4;325(17):1784-1786.
doi: 10.1001/jama.2021.4385.

Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients

Brian J Boyarsky  1 , William A Werbel  2 , Robin K Avery  2 , Aaron A R Tobian  3 , Allan B Massie  1 , Dorry L Segev  1 , Jacqueline M Garonzik-Wang  1
Affiliations

Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients

Brian J Boyarsky et al. JAMA. .

Abstract

This study quantifies antispike protein antibody responses to first-dose messenger RNA (mRNA) COVID-19 vaccines in solid organ transplant recipients to better understand the immunogenicity of the vaccines in immunocompromised individuals.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Avery reported receiving grant support from Aicuris, Astellas, Chimerix, Merck, Oxford Immunotec, Qiagen, and Takeda/Shire. Dr Segev reported serving as a consultant to and receiving honoraria for speaking from Sanofi, Novartis, CSL Behring, Jazz Pharmaceuticals, Veloxis, Mallincrodt, and Thermo Fisher Scientific. No other disclosures were reported.

Comment in

References

    1. Boyarsky BJ, Ou MT, Werbel WA, et al. . Early development and durability of SARS-CoV-2 antibodies among solid organ transplant recipients: a pilot study. Transplantation. Published online January 19, 2021. doi:10.1097/tp.0000000000003637 - DOI - PMC - PubMed
    1. Klein SL, Pekosz A, Park HS, et al. . Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J Clin Invest. 2020;130(11):6141-6150. doi:10.1172/JCI142004 - DOI - PMC - PubMed
    1. Patel EU, Bloch EM, Clarke W, et al. . Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers. J Clin Microbiol. 2021;59(2):e02257-20. doi:10.1128/JCM.02257-20 - DOI - PMC - PubMed
    1. Higgins V, Fabros A, Kulasingam V. Quantitative measurement of anti-SARS-CoV-2 antibodies: analytical and clinical evaluation. J Clin Microbiol. Published online March 19, 2021. doi:10.1128/JCM.03149-20 - DOI - PMC - PubMed
    1. Jackson LA, Anderson EJ, Rouphael NG, et al. ; mRNA-1273 Study Group . An mRNA vaccine against SARS-CoV-2—preliminary report. N Engl J Med. 2020;383(20):1920-1931. doi:10.1056/NEJMoa2022483 - DOI - PMC - PubMed

Publication types